These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1280 related items for PubMed ID: 21333426

  • 21. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators.
    Nephrol Dial Transplant; 2018 Mar 01; 33(3):477-489. PubMed ID: 28379536
    [Abstract] [Full Text] [Related]

  • 26. Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
    Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F.
    Clin J Am Soc Nephrol; 2023 Jan 01; 18(1):36-46. PubMed ID: 36719158
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Treatment of autosomal dominant polycystic kidney disease (ADPKD) - Tolvaptan].
    Cirillo M.
    G Ital Nefrol; 2016 Jan 01; 33(5):. PubMed ID: 27796022
    [Abstract] [Full Text] [Related]

  • 29. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
    Casteleijn NF, Messchendorp AL, Bae KT, Higashihara E, Kappert P, Torres V, Meijer E, Leliveld AM.
    Clin Exp Nephrol; 2017 Jun 01; 21(3):375-382. PubMed ID: 27339446
    [Abstract] [Full Text] [Related]

  • 30. [Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].
    Yamada Y, Fujiki H, Mizuguchi H, Takeshita Y, Hattori K, Ohmoto K, Aihara M, Nagano K, Isakari Y, Yamamoto M, Yamamura Y.
    Nihon Yakurigaku Zasshi; 2022 Jun 01; 157(4):254-260. PubMed ID: 35781456
    [Abstract] [Full Text] [Related]

  • 31. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
    Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):645-652. PubMed ID: 28992127
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 35. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, Cabrera MV, Walz G, O'Reilly K, Robinson P.
    BMC Nephrol; 2018 Feb 13; 19(1):37. PubMed ID: 29439650
    [Abstract] [Full Text] [Related]

  • 36. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K, Fox A, Gilbert R.
    Arch Dis Child; 2016 Sep 13; 101(9):e2. PubMed ID: 27540244
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
    Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, Estilo A.
    Am J Kidney Dis; 2023 Mar 13; 81(3):281-293.e1. PubMed ID: 36191725
    [Abstract] [Full Text] [Related]

  • 39. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA.
    Drugs; 2019 Feb 13; 79(3):303-313. PubMed ID: 30689194
    [Abstract] [Full Text] [Related]

  • 40. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
    Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M.
    Am J Kidney Dis; 2024 Sep 13; 84(3):275-285.e1. PubMed ID: 38608748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 64.